Rep. Lisa C. McClain Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative Lisa C. McClain (R-Michigan) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on October 22nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on September 11th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of FMC (NYSE:FMC) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Merit Medical Systems (NASDAQ:MMSI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Darden Restaurants (NYSE:DRI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Kenvue (NYSE:KVUE) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Beacon Financial (NYSE:BBT) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of British American Tobacco (NYSE:BTI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Rollins (NYSE:ROL) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of MGP Ingredients (NASDAQ:MGPI) on 9/25/2025.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $53.24 on Friday. The company has a market capitalization of $237.70 billion, a PE ratio of 14.63, a price-to-earnings-growth ratio of 2.43 and a beta of 0.68. The firm has a fifty day simple moving average of $56.55 and a 200-day simple moving average of $62.45. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $115.26.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is 22.53%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. True Wealth Design LLC raised its position in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC raised its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the period. North Capital Inc. acquired a new stake in Novo Nordisk A/S during the 1st quarter worth about $27,000. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter worth about $30,000. Finally, NewSquare Capital LLC raised its holdings in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on NVO shares. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Novo Nordisk A/S in a research report on Tuesday, October 14th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $76.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.